A Phase 1/2 interventional study of nikkomycin Z and Placebo in Coccidioidomycosis, sponsored by University of Arizona. Terminated at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-04-16.
Sponsored by University of Arizona · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Coccidioidomycosis with a site in United States — 3 open to participants now, 3 under way, none of them phase 3. Coccidioidomycosis · United States.
Among the 16 studies in Coccidioidomycosis with a site in United States, this one is the 10th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2007, is the only one in phase 1/2, and was the 3rd registered.
21 studies on the registry are indexed under Coccidioidomycosis; 4 are open to participants now.
Browse Coccidioidomycosis studies →3 of the 16 studies in Coccidioidomycosis with a site in United States are open now. Recruiting first, the newest first:
Fariba Donovan · Sites in United States
Ages 18+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 2–100
University of Minnesota · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 2 Coccidioidomycosis studies recruiting now, 1 sets no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 3 · Phase 4 1
First in 2005; this study’s year is marked. 2 started in 2007.
This study's enrollment of 6 is below the median of 48 across 13 interventional studies indexed under Coccidioidomycosis.
Median enrollment 48 across the 11 interventional studies, 598 across the 3 observational. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 16 have an industry lead sponsor. The 10 most frequent:
University of Arizona is the lead sponsor of 477 studies on the registry; 88 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 30 (59%) have results posted.
University of Arizona has 3 studies filed under Coccidioidomycosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Coccidioidomycosis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07385638Fariba DonovanOlorofim in Early Coccidioidal Meningitis | 2027-03-15 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Coccidioidomycosis with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if nikkomycin Z is safe when administered at different dose levels for 14 days. The study will also determine blood levels and urinary excretion of nikkomycin Z in relation to dose administered. Patients with mild forms of Valley Fever pneumonia will be eligible to participate and will be allocated to receive treatment with nikkomycin Z (various doses) or a placebo. A secondary goal of this study is to evaluate the effectiveness and dose response of nikkomycin Z in an exploratory analysis.
Every year there are 50,000 new U.S. cases of coccidioidomycosis (Valley Fever). The majority of these illnesses occur as a result of endemic exposure in Arizona and California. The benefits of antifungal therapy for uncomplicated disease are not currently established. Current therapies for serious and complicated forms of coccidioidomycosis are only partially effective and in themselves are unable to eradicate the fungus from sites of infection, commonly resulting in breakthrough infection and/or relapse. Nikkomycin Z is effective in the mouse model and results in improved microbiological response over fluconazole.
The goals of this study include: 1) Evaluating the safety and tolerance of nikkomycin Z following administration of multiple doses (50 mg Q 12 h to 750 mg Q 8 h) for two week and 2) Evaluating the pharmacokinetics of nikkomycin Z after single and multiple doses in relationship to dose. The study will include patients with uncomplicated Coccidioides pneumonia (mild illness) which will allow exploratory analysis of efficacy and dose response based on biomarkers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
nikkomycin Z 50 mg BID x 14 days
Drug: nikkomycin Z
nikkomycin Z nikkomycin Z 250 mg BID x 14 days
Drug: nikkomycin Z
nikkomycin Z 500 mg BID x 14 days
Drug: nikkomycin Z
nikkomycin Z 750 BID x 14 days
Drug: nikkomycin Z
placebo BID x 14 days
Drug: Placebo
Stage I: Multiple rising doses. Doses packaged on a unit dose basis in 50 and 250 mg capsules. Subjects take 1-3 capsules per dosing block for 14 days unless ADE or study withdrawal. Dose escalation unless a dose-limiting adverse effect is noted. Subjects assigned to BID dosing will receive 28 doses and subjects assigned to TID dosing will receive 42 doses. * 50 mg BID (n=4) vs placebo capsule BID (n=1) * 50 mg BID (n=4) vs 250 mg BID (n=4) vs Placebo capsule BID (n=2) * 250 mg BID (n=4) vs 500 mg BID (n=4) vs Placebo capsule BID (n=2) * 500 mg BID (n=4) vs Placebo capsule BID (n=1) At least 4 subjects complete lower dose before randomization includes next higher dose. Stage II will be a single dose level selected based on pharmacodynamics and safety from Stage I for 20 additional subjects using 4:1 randomization.
Placebo comparator
Concentration of Nikkomycin Z in the Blood Over Time (AUC)
Time frame: 0, 0.25, 0.5, 0.75, 1.0, 1.5, 2 , 3, 4, 6, 8 and 12 h hours post-dose on Day 1 and Day 14
Highest Concentration of Nikkomycin Z in the Blood (Cmax)
Time frame: 0, 0.25, 0.5, 0.75, 1.0, 1.5, 2 , 3, 4, 6, 8 and 12 h hours post-dose on Day 1 and Day 14
| Milestone | A - First Dose Level | B - Second Dose Level | C - Third Dose Level | D - Fourth Dose Level | Placebo |
|---|---|---|---|---|---|
| Started | 4 | 1 | 0 | 0 | 1 |
| Completed | 4 | 1 | 0 | 0 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| mg*hr/L | A - First Dose Level (n=5) | B - Second Dose Level (n=10) | C - Third Dose Level (n=10) | D - Fourth Dose Level (n=5) |
|---|---|---|---|---|
| Day 1 | 3.444 ± 0.710 | 19.923 ± NA | — | — |
| Day 14 | 3.900 ± 1.583 | 24.045 ± NA | — | — |
| mg/L | A - First Dose Level (n=5) | B - Second Dose Level (n=10) | C - Third Dose Level (n=10) | D - Fourth Dose Level (n=5) |
|---|---|---|---|---|
| Day 1 | 0.710 ± 0.188 | 3.748 ± NA | — | — |
| Day 14 | 0.811 ± 0.248 | 4.275 ± NA | — | — |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| A - First Dose Level (n=5) | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| B - Second Dose Level (n=10) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| C - Third Dose Level (n=10) | — | — | — |
| D - Fourth Dose Level (n=5) | — | — | — |
| Placebo | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Event | A - First Dose Level (n=5) | B - Second Dose Level (n=10) | C - Third Dose Level (n=10) | D - Fourth Dose Level (n=5) | Placebo |
|---|---|---|---|---|---|
| HeadacheGeneral disorders | 3/4 | 1/1 | — | — | 1/1 |
| NauseaGastrointestinal disorders | 1/4 | 0/1 | — | — | 1/1 |
| Left lung noduleRespiratory, thoracic and mediastinal disorders | 0/4 | 1/1 | — | — | 0/1 |
| Right temple painGeneral disorders | 0/4 | 1/1 | — | — | 0/1 |
| HypotensionVascular disorders | 1/4 | 0/1 | — | — | 0/1 |
| Near syncopeGeneral disorders | 1/4 | 0/1 | — | — | 0/1 |
| DiarrheaGastrointestinal disorders | 1/4 | 0/1 | — | — | 0/1 |
| Dry mouthGeneral disorders | 1/4 | 0/1 | — | — | 0/1 |
| InsomniaGeneral disorders | 1/4 | 0/1 | — | — | 0/1 |
| Cataract surgeryEye disorders | 1/4 | 0/1 | — | — | 0/1 |
| Age, Categorical(Participants) | A - First Dose Level (n=5) | B - Second Dose Level (n=10) | C - Third Dose Level (n=10) | D - Fourth Dose Level (n=5) | Placebo | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 1 | 0 | 0 | 1 | 6 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | A - First Dose Level (n=5) | B - Second Dose Level (n=10) | C - Third Dose Level (n=10) | D - Fourth Dose Level (n=5) | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 1 | 0 | 0 | 0 | 1 | 2 |
| Male | 3 | 1 | 0 | 0 | 0 | 4 |
| Ethnicity (NIH/OMB)(Participants) | A - First Dose Level (n=5) | B - Second Dose Level (n=10) | C - Third Dose Level (n=10) | D - Fourth Dose Level (n=5) | Placebo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 4 | 1 | 0 | 0 | 1 | 6 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | A - First Dose Level (n=5) | B - Second Dose Level (n=10) | C - Third Dose Level (n=10) | D - Fourth Dose Level (n=5) | Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 4 | 1 | 0 | 0 | 1 | 6 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | A - First Dose Level (n=5) | B - Second Dose Level (n=10) | C - Third Dose Level (n=10) | D - Fourth Dose Level (n=5) | Placebo | Total |
|---|---|---|---|---|---|---|
| United States | 4 | 1 | — | — | 1 | 6 |
Plan to share: Yes — De-identified data may be shared for legitimate use to further nikkomycin Z development.
Supporting information: Study protocol, Informed consent form
Time frame: Study was terminated due to poor enrollment. Study report was not generated beyond safety data.
Access criteria: Contact Valley fever Solutions - current license for development.
The record gives a start of Sep 2007, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2025, 15 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nikkomycin